2021 Medicare Advantage Stars
Primary Care Incentive Program:
Clinical Quality Measures
This presentation is the property of Highmark Health and is proprietary and confidential. The material contained in it is educational and informational, is intended for this audience only, and cannot be rebroadcasted to unapproved audiences. This presentation may not be recorded in any manner including, without limitation, audio, video, photograph, screenshot, or by any other means or in any other media. Broadcasting, publication, or sharing of these materials without Highmark’s expressed permission is strictly prohibited.
Best Practices Disclaimer:

The guidance, best practices and guidelines (referred to as “best practices”) provided to you are presented for your consideration and assessment only. Please assess whether the described best practices are appropriate for you. There are no requirements that you use the best practices, and the best practices are not required for any Highmark program or initiative. Please note that the successful implementation of any program or initiative depends upon many factors and variables. Therefore, Highmark makes no representation with respect to the described best practices and whether the practices will positively impact your reimbursement, value based payment or performance under a Highmark program or initiative.

The best practices are not intended to situate Highmark as a provider of medical services or dictate the diagnosis, care or treatment of patients. Your medical judgment remains independent with respect to all medically necessary care to your patients.
Agenda

1. Overview of the 2021 Stars program.
   - Measures Included
   - General Guidelines

2. Descriptions of each Measure
   - Best Practices, Supplemental Data Submissions, Member Benefits, Additional Information

3. Profiled Measures
   - Best Practices
### 2021 Medicare Advantage Stars Primary Care Incentive Program: Clinical Quality Measures

<table>
<thead>
<tr>
<th>Measure</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>C01:</td>
<td>Breast Cancer Screening</td>
</tr>
<tr>
<td>C02:</td>
<td>Colorectal Cancer Screening</td>
</tr>
<tr>
<td>C12:</td>
<td>Osteoporosis Management in Women who had a Fracture</td>
</tr>
<tr>
<td>C13:</td>
<td>Comprehensive Diabetes Care: Eye Exam (retinal) performed</td>
</tr>
<tr>
<td>C14:</td>
<td>Comprehensive Diabetes Care: Medical Attention for Nephropathy</td>
</tr>
<tr>
<td>C15:</td>
<td>Comprehensive Diabetes Care: HbA1c Control (≤9%)</td>
</tr>
<tr>
<td>C16:</td>
<td>Controlling High Blood Pressure</td>
</tr>
<tr>
<td>C21:</td>
<td>All Cause Readmission Rate – Medicare Advantage</td>
</tr>
<tr>
<td>C22:</td>
<td>Statin Therapy for Patients with Cardiovascular Disease</td>
</tr>
<tr>
<td>D10:</td>
<td>Medication Adherence for Diabetes Medications</td>
</tr>
<tr>
<td>D11:</td>
<td>Medication Adherence for Hypertension (RASA)</td>
</tr>
<tr>
<td>D12:</td>
<td>Medication Adherence for Cholesterol (Statins)</td>
</tr>
<tr>
<td>D13:</td>
<td>Medication Therapy Management</td>
</tr>
<tr>
<td>D14:</td>
<td>Medication Adherence for Diabetes Medications</td>
</tr>
<tr>
<td>HOS1:</td>
<td>Screening for Future Fall Risk</td>
</tr>
<tr>
<td>HOS2:</td>
<td>Screening for Bladder Control</td>
</tr>
<tr>
<td>HOS3:</td>
<td>Monitoring for Physical Activity</td>
</tr>
<tr>
<td>DMC18:</td>
<td>Follow Up ED for People with Multiple Chronic Conditions</td>
</tr>
<tr>
<td>DMC21:</td>
<td>TRC Patient Engagement After Inpatient Discharge</td>
</tr>
<tr>
<td>DMC19:</td>
<td>TRC Medication Reconciliation Post-Discharge</td>
</tr>
</tbody>
</table>

*Not a CMS measure. Not included in aggregate Stars score calculation.*
Measure Design

A HEDIS or PQA measure specification consists of defined sets and subsets of criteria needed to identify and calculate the concept being measured.

*Each measure includes:*

- **Numerator** - A description of services counted.
- **Denominator** - The definition of an eligible population.
- **Exclusion** - Removes a member from the denominator.

*Also defined for each measure:*

- Value Set
- Reporting Instructions
- Calculation Logic

Compliance
# General Guidelines for Exclusion

<table>
<thead>
<tr>
<th>Hospice</th>
<th>Continuous Enrollment &amp; Anchor Dates</th>
<th>Palliative Care</th>
<th>End Stage Renal Disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Hospice benefits are determined by source data from CMS that is provided to the health plan directly.</td>
<td>• Each measure has an enrollment period with gap defined by HEDIS Part C or PQA Part D specifications. This helps ensure adequate time to render services.</td>
<td>• Exclusions for palliative care are specified in HEDIS measures where the services being captured may not be of benefit for this population or may not be in line with patients’ goals of care.</td>
<td>• For members to be excluded from the measure sets with End Stage Renal Disease source data is provided from CMS to the health plan directly.</td>
</tr>
<tr>
<td>• Members who use hospice benefits any time during the measurement year, regardless of when the services began, are excluded from all Part C HEDIS and Part D PQA measures.</td>
<td>• Members must be enrolled and have benefits through anchor dates identified within each measure specification.</td>
<td>• Members receiving palliative care are captured and excluded via claims as defined by the HEDIS Value sets (<a href="#">Palliative Care Assessment Value Set</a>; <a href="#">Palliative Care Encounter Value Set</a>; <a href="#">Palliative Care Intervention Value Set</a>) during the measurement year</td>
<td></td>
</tr>
<tr>
<td>• Documentation that a member is near the end of life (e.g., comfort care, DNR, DNI) or is in palliative care does not meet criteria for the Hospice exclusion.</td>
<td>• Death and disenrollment will not remove a member from a measure if the continuous enrollment criteria is met.</td>
<td>• Codes for Palliative Care G9054; M1017; Z51.5</td>
<td></td>
</tr>
</tbody>
</table>

Proprietary and Confidential | 2021
### STAR Measures with Advanced Illness and Frailty Exclusions

#### Source: HEDIS® 2021

#### Frailty
- Per HEDIS guidelines Frailty exclusions are determined via administrative claim data only.

- For exclusion to be captured at least one claim that includes frailty (Frailty Value set) must be submitted during the measurement year.

- For Osteoporosis, the diagnosis must be captured during the intake period of July 1, 2020-June 30, 2021 through the end of the measurement year December 31, 2021.

#### Advanced Illness
- Per HEDIS guidelines Advanced Illness exclusions are determined via administrative claims data only. These can be submitted with telemedicine visit claims.

- For exclusion, any of the following during the measurement year or year prior to the measurement year will be applied:
  - At least two outpatient visits (OBs, ED, or non acute inpatient on different date of service with an advanced illness diagnosis
  - At least one acute inpatient encounter with an advanced illness diagnosis
  - A dispensed dementia medication

<table>
<thead>
<tr>
<th>Measure Description</th>
<th>Must have both elements of Frailty AND Advanced Illness in population 66 yrs. of age or older</th>
<th>Can qualify under Frailty alone in population 81 yrs. of age or older</th>
</tr>
</thead>
<tbody>
<tr>
<td>Controlling High Blood Pressure</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Breast Cancer Screening</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>Colorectal Cancer Screening</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>CDC: HbA1c Controlled</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>CDC: Retinal Eye Exam</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>CDC: Medical Attention for Nephropathy</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>Statin Therapy for Patients with Cardiovascular Disease</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>Osteoporosis Management in Women Who Had a Fracture</td>
<td>Yes</td>
<td></td>
</tr>
</tbody>
</table>
### C01: Breast Cancer Screening

**Source:** HEDIS® 2021 (BCS)

**Measure weight:** 1  
**5 Star:** 85%

Percentage of female members 50–74 years of age who had a mammogram to screen for breast cancer.

<table>
<thead>
<tr>
<th>Numerator</th>
<th>Denominator</th>
<th>Exclusions</th>
</tr>
</thead>
<tbody>
<tr>
<td>One or more mammograms during the measurement year or the 15 months prior to the measurement year (OCT 1, 2019 – DEC 31, 2021)</td>
<td>Female members 52–74 years of age as of the last date of the measurement year (female members who were 50 years of age or older as of OCT 2019)</td>
<td>• Those who had a bilateral mastectomy any time during the member’s history through the last day of the measurement year</td>
</tr>
</tbody>
</table>

Frailty and Advanced Illness exclusions apply
**C01: Breast Cancer Screening**

Source: HEDIS® 2021 (BCS)

Percentage of female members 50–74 years of age who had a mammogram to screen for breast cancer.

---

**Supplemental Data Submission**

Clinical Quality Feedback (CQF) function is available through the Provider Portal on NaviNet and accepts submission of numerator compliant screening tests and exclusionary data for Highmark members.

---

**Best Practice**

Take the opportunity to cover personal review of member preventive screening needs through the Annual Wellness Visit/Initial Preventive Physical Exam (Welcome to Medicare). Make most of this opportunity to communicate preventive care.

Supply members with an order to enable flexibility in scheduling through walk in centers and breast cancer screening events.

Issue member letters from your practice to non-compliant member to explain why regular breast cancer screening is important.

Note: If screening events are free, claim may not be submitted through our member’s insurance. Please advise members if they are able to attend a free screening event to list the PCP so that copies of the results may be obtained for submission via the CQF.

Note: As we move into 2021, COVID will still play a crucial role in quality measures. Please make sure to schedule all Mammograms as soon as possible in 2021 as appointments may once again be limited.

---

**Medicare Advantage Member Benefits**

Medicare Advantage denotes screening mammography as a covered in full benefit.

**Limits**: One screening during a calendar year.

Please distinguish between screening and diagnostic testing.
C02: Colorectal Cancer Screening  
Source: HEDIS® 2021 (COL)  
Measure weight: 1  
5 Star: 85%  

### Percentage of members 50–75 years of age who had appropriate screening for colorectal cancer

<table>
<thead>
<tr>
<th>Numerator</th>
<th>Denominator</th>
<th>Exclusions</th>
</tr>
</thead>
</table>
| One or more screenings for colorectal cancer. Appropriate screenings are defined by any one of the five criteria below:  
- **FOBT** – During the Measurement Year. Regardless of FOBT type, guaiac (gFOBT) or immunochemical (FIT), assume that the required number of samples were returned.  
- **Flexible Sigmoidoscopy** – During the Measurement Year or the four years prior to the measurement year.  
- **Colonoscopy** – During the Measurement Year or the nine years prior to the measurement year.  
- **CT colonography** during the measurement year or the four years prior to the measurement year.  
- **FIT-DNA** during the measurement year or the two years prior to the measurement year.  
*Please refer to the Primary Care Incentive Measure Guide for testing compliance dates of service* | Percentage of members 51–75 years of age who had appropriate screening for colorectal cancer | • Those with a diagnosis of colorectal cancer  
• Those with evidence of a total colectomy |

Frailty and Advanced Illness exclusions apply
C02: Colorectal Cancer Screening
Source: HEDIS® 2021 (COL)

Percentage of members 50–75 years of age who had appropriate screening for colorectal cancer.

**Supplemental Data Submission**

CQF function is available through the Provider Portal on NaviNet and accepts submission of numerator compliant screening tests and exclusionary data for Highmark members who had services prior to being a Highmark carrier.

**Best Practice**

The use of Fecal Occult Blood detection testing is accepted as a HEDIS numerator compliant form of non-invasive colorectal screening. This testing is required to be completed annually. Many practices have distributed home testing kits to gain compliance. Information on how a practice can work with a supplier to purchase and distribute FOBT kits can be found on the Provider Resource Center under Practice Tools for Colorectal Cancer.

If your practice does not distribute kits, encourage members to complete FOB tests distributed by Highmark Health Plan and its partners. Members may call Highmark’s customer service anytime after April 1st and request a home FIT Kit be directly shipped.

**Medicare Advantage Member Benefits**

Medicare Advantage denotes screening colonoscopy, sigmoidoscopy, CT colonography, and fecal occult blood detection testing as a covered in full benefit. Screening benefit schedule limits:

- FOBT Limit 1 per calendar year.
- FIT-DNA (Cologuard) Limit 1 every 3 calendar years
- Colonoscopy once every 10 years, or 48 months after a previous flexible sigmoidoscopy.
- Sigmoidoscopy: Every 48 months.
- CT colonography: Limit once every 5 calendar years

Please distinguish between screening and diagnostic testing.
C12: Osteoporosis Management in Women who had a Fracture

Source: HEDIS® 2021 (OMW)

Percentage of female members 67–85 years of age who suffered a fracture and who had either a bone mineral density (BMD) test or prescription for a drug to treat or prevent osteoporosis within 180 days of the fracture date.

<table>
<thead>
<tr>
<th>Numerator</th>
<th>Denominator</th>
<th>Exclusions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Those female members age 67-85 who had suffered a fracture and who had either a BMD test or filled a prescription for a drug to treat or prevent osteoporosis within 180 days of the fracture date.</td>
<td>Female members, 67–85 yrs. of age by the end of the measurement year who suffered a fracture. Fractures of finger, toe, face and skull are not included in this measure.</td>
<td>• Those who had a BMD test 24 months prior to the earliest date of service during the index period with diagnosis of fracture (index episode start date).</td>
</tr>
<tr>
<td>The drug classifications of Estrogen and Sex Hormone combinations are not included in numerator compliance</td>
<td>Intake period is defined as a 12-month window that begins 6 months prior to the measurement year and ends after 6 months into the measurement year. The intake period is used to capture the first fracture.</td>
<td>• Those who had a claim encounter for osteoporosis therapy during the 365 days prior to the episode date</td>
</tr>
<tr>
<td></td>
<td>Intake Period: JULY 1, 2020 – JUNE 30, 2021</td>
<td>• Those who received a dispensed prescription or had an active prescription to treat osteoporosis during the 365 days prior to the index episode start date.</td>
</tr>
<tr>
<td></td>
<td>* Remember for 2021 this Measure no longer has a minimum denominator requirement. All members will be scored for this measure.</td>
<td>• Those without pharmacy benefits through Highmark.</td>
</tr>
</tbody>
</table>

Frailty and Advanced Illness exclusions apply.
Best Practice

- Proper coding is essential in correctly identifying members who have recently suffered a fracture. Recent or new fractures are fractures that are not yet healed and should be coded as such. However, if a fracture is healed, coding should indicate that the member has a history of fracture. In this case, providers are encouraged to use the appropriate z-code from the list below* when coding for “History of Fracture”.
  - Example ICD 10 Codes:
    - Z87.310 Personal history of (healed) osteoporosis fracture
    - Z87.311 Personal history of (healed) other pathological fracture
    - Z87.312 Personal history of (healed) stress fracture
    - Z87.81 Personal history of (healed) traumatic fracture

*List is not comprehensive and is intended to provide educational support only. Providers must follow CMS coding regulations and guidelines.

Fracture Prevention/Assess Contributing Factors:

- Screen members at risk for osteoporosis (bone mineral density test)
- Assess Risk of Falls
- Screen for Urinary Incontinence
- Review and evaluate Use of High Risk Medications

Osteoporosis Medications: Bisphosphonates are a class of drugs that prevent the loss of bone density, used to treat osteoporosis and similar diseases. Bisphosphonates and other agents included as compliant as a drug to treat osteoporosis for HEDIS OMW: alendronate, alendronate-cholecalciferol, ibandronate, risedronate, zoledronic acid (Reclast and Zometa), abaloparatide, denosumab (Prolia), raloxifene, romosozumab, and teriparadate.

* Alendronate is a Tier 1 low cost option on all Highmark Medicare formularies (Fosamax and Binosto)

Note: Monotherapy with calcium supplements or Vitamin D supplements (cholecalciferol or ergocalciferol) will not meet compliance for this measure.
C12: Osteoporosis Management in Women who had a Fracture

Source: HEDIS® 2021 (OMW)

Percentage of female members 67–85 years of age who suffered a fracture and who had either a bone mineral density (BMD) test or prescription for a drug to treat or prevent osteoporosis within 180 days of the fracture date.

### Best Practice

- Utilize Highmark vendor for Highmark Medicare Advantage members requiring or requesting the convenience of in-home testing.
- Patients with current fractures maybe under an orthopedic specialist care. Discuss with the orthopedic provider a timeline for required X-ray testing (monitoring of healing) and request DEXA scan be completed during the same outing; or discuss the opportunity of prescribing an osteoporosis medication after the four-month healing process.
- Completed services will be reflected in your monthly Stars reports. NOTE: Additional Incentive opportunity exists on this measure for BMD studies completed without assistance of Highmark vendor.
- Reference vendor related FAQs located under Highmark In-Home Programs on the Provider Resource Center:
  - Provider-Resource-Center/Value-Based-Reimbursement-Programs/Medicare-Advantage-Member-and-Provider-Programs/Member-Programs-&-Materials/Highmark-In-Home-Programs

### Supplemental Data Submission

CQF function is available through the Provider Portal on NaviNet and accepts submission of numerator compliance and exclusionary data for Highmark members who had services prior to being a Highmark carrier.

Please maintain documentation within the member’s medical record for future submission.

### Medicare Advantage Member Benefits

Covered in full. Office visit or site of service co-pay may apply.
Medicare Advantage preventive schedule limit: One BMD test every 24 months
Comprehensive Diabetes Care Measures
Source: HEDIS® 2021 (component of CDC)

CDC Measures encompass three components:
• Eye Exam (Retinal) Performed
• Medical Attention for Nephropathy
• HbA1c < 9

Diabetics are defined by:

*Pharmacy data:* members who were dispensed insulin or oral hypoglycemics/antihyperglycemics during the measurement year or the year prior on an ambulatory basis

*Note:* Monotherapy glucophage/metformin is not included because it is used to treat conditions other than diabetes; members with diabetes on these medications are identified through diagnosis codes only. NCQA has posted a complete list of medications and NDC codes to [www.ncqa.org](http://www.ncqa.org)

*Claim/encounter data:* members who had either of the following during the measurement year or year prior
  - Two outpatient settings including outpatient visits, observation visits, telephone visits, e-visits or virtual check-ins, ED visits or non-acute inpatient encounters (without telehealth) on different dates of service with a dx of diabetes
  - One face-to-face encounter in an acute inpatient setting, with a diagnosis of diabetes
Identifies adult diabetic members who received an eye screening for diabetic retinal disease.

<table>
<thead>
<tr>
<th>Numerator</th>
<th>Denominator</th>
<th>Exclusions</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Diabetics who received a retinal or dilated eye exam by an eye care professional (optometrist or ophthalmologist) in the measurement year</td>
<td>Diabetic members age 18–75 years by the end of the measurement year and who were enrolled in the plan at the end of the measurement year.</td>
<td>• Diagnosis of gestational or steroid-induced diabetes during the measurement year or the year prior to the measurement year.</td>
</tr>
<tr>
<td>• A negative retinal or dilated eye exam (negative for retinopathy) by an eye care professional in the year prior to the measurement year.</td>
<td></td>
<td>• Diagnosis of Polycystic Ovarian Syndrome during the measurement year or the year prior to the measurement year.</td>
</tr>
<tr>
<td>• Bilateral eye enucleation any time during the member’s history through December 31st</td>
<td>Please refer to Diabetic member definitions on Slide 16 – also applicable to this measure.</td>
<td>For exclusions to remove member from the denominator, member must not have a face-to-face encounter in any setting, with a diagnosis of diabetes, during the measurement year or year prior to the measurement year.</td>
</tr>
</tbody>
</table>

Eye exam claims submitted by optometrist or ophthalmologist with the corresponding E11.9 Dx code are recorded as negative for retinopathy

Frailty and Advanced Illness exclusions apply
Identifies adult diabetic members who received an eye screening for diabetic retinal disease.

<table>
<thead>
<tr>
<th>Measure Specific CPT2 Codes for Reporting as Non-Eye Care Provider</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>2022F</strong></td>
</tr>
<tr>
<td><strong>2023F</strong></td>
</tr>
<tr>
<td><strong>2024F</strong></td>
</tr>
<tr>
<td><strong>2025F</strong></td>
</tr>
<tr>
<td><strong>2026F</strong></td>
</tr>
<tr>
<td><strong>2033F</strong></td>
</tr>
</tbody>
</table>
## Best Practice

- Complete AWV and assessment of diabetic member preventive care/disease progression indicators for all Value Based Reimbursement quality programs.
- Provide script or referral to ophthalmologist or optometrist to complete the exam. Use referral form with results to be faxed/email back to the PCP. Reference Diabetic retinal eye preventive screening requirement on referral sheet.
- Reference measure specifications for appropriate CPT2 code application. For measure specific educational material on CPT2 codes, please contact your Clinical Transformation Consultant or Provider Account Liaison.
- Issue member letters from your practice to non compliant member to explain why retinal eye screening is important on an annual basis.

## Supplemental Data Submission

CQF function is available through the Provider Portal on NaviNet and accepts submission of numerator compliant screening tests and exclusionary data for Highmark members who had services prior to being a Highmark carrier.

** The code 3072F which indicates a member has had a negative retinal eye exam last year can be resulted via the clinical feedback loop. This data point must be submitted using the current year (date documentation reviewed) to indicate the eye exam results were negative in the prior year. The negative eye exam report must be secured within the member’s medical record.

## Medicare Advantage Member Benefits

Covered in full. Office visit or site of service co-pay may apply.

Routine vision exam covered every calendar year.
C14: Comprehensive Diabetes Care – Medical Attention for Nephropathy

Source: HEDIS® 2021 (component of CDC)

Measure weight: 1 5 Star: 98%

Identifies adult diabetic members who had medical attention for nephropathy.

<table>
<thead>
<tr>
<th>Numerator</th>
<th>Denominator</th>
<th>Exclusions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Those with evidence of nephropathy or a nephropathy screening test during the measurement year.</td>
<td>Diabetic members age 18–75 years by the end of the measurement year and who were enrolled in the plan at the end of the measurement year.</td>
<td>• Diagnosis of gestational or steroid-induced diabetes during the measurement year or the year prior to the measurement year. • Diagnosis of Polycystic Ovarian Syndrome during the measurement year or the year prior to the measurement year.</td>
</tr>
<tr>
<td>• A claim encounter with a code to indicate evidence of treatment for nephropathy.</td>
<td>[Please refer to Diabetic member definitions on Slide 16 – also applicable to this measure.]</td>
<td>For exclusions to remove member from the denominator, member must not have a face-to-face encounter in any setting, with a diagnosis of diabetes, during the measurement year or year prior to the measurement year.</td>
</tr>
<tr>
<td>• A nephrologist visit during the measurement year.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Evidence of ACE inhibitor or ARB therapy in the measurement year.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Lab claim for a urinalysis that included microalbumin</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Note: Documentation of ACEI/ARB medication regimen in current measurement year results as numerator compliance for this measure.

Frailty and Advanced Illness exclusions apply
# C14: Comprehensive Diabetes Care – Medical Attention for Nephropathy

**Source:** HEDIS® 2021 (component of CDC)

Identifies adult diabetic members who had medical attention for nephropathy.

## Best Practice

- Complete AWV and assessment of diabetic member preventive care/disease progression indicators for all Highmark quality incentive programs.
- Hardwire EHR to trigger preventive schedules - this is an annual test requirement
- Assure processes are in place to submit appropriate test billing.
- Report when appropriate the CPTII code 4010F - ACE inhibitor or ARB therapy prescribed or currently being taken.
- Review recent hospitalizations within the measurement year for urine screens while member was in the inpatient setting. Services billed in an inpatient setting will be billed as a bundle and may not be recorded for gap closure.
- Issue member letters from your practice (with order enclosed) to non-compliant member to explain why regular micro albumin screening is important.

## Supplemental Data Submission

CQF function is available through the Provider Portal on NaviNet and accepts submission of numerator compliant screening tests and exclusionary data for Highmark members who have evidence of ACEI/ARB therapy recorded appropriately in the medical record or have study micro albumin study completed outside of claim submission.

**Note:** Specifications denote testing as numerator compliance; therefore, results of urine protein test do not need to be submitted.

## Medicare Advantage Member Benefits

Covered in full. Office visit or site of service co-pay may apply.
### C15: Comprehensive Diabetes Care – HbA1c Control ≤9%

Source: HEDIS® 2021 (component of CDC)

Percentage of members 18–75 years of age with diabetes (type 1 and type 2) whose most recent Hemoglobin A1C is ≤9.0%. The measure is reported as an inverted rate \[1-(\text{numerator/eligible population})\]. Higher rate of compliance demonstrates better performance.

<table>
<thead>
<tr>
<th>Numerator</th>
<th>Denominator</th>
<th>Exclusions</th>
</tr>
</thead>
</table>
| Diabetic members who received at least one HbA1c screening during the measurement year with the last HbA1c test result for the measurement year ≤ 9%. | Diabetic members age 18–75 years by the end of the measurement year and who were enrolled in the plan at the end of the measurement year. Please refer to Diabetic member definitions on Slide 16 – also applicable to this measure. | • Diagnosis of gestational or steroid-induced diabetes during the measurement year or the year prior to the measurement year.  
• Diagnosis of Polycystic Ovarian Syndrome during the measurement year or the year prior to the measurement year. For exclusions to remove member from the denominator, member must not have a face-to-face encounter in any setting, with a diagnosis of diabetes, during the measurement year or year prior to the measurement year. |

Control is demonstrated by CPTII Codes:  
3044F HbA1c: < 7.0%  
3051F HbA1c: ≥ 7.0 and < 8.0%  
3052F HbA1c: ≥ 8.0 and ≤ 9.0%  

Frailty and Advanced Illness exclusions apply
C15: Comprehensive Diabetes Care – HbA1c Control ≤9%

Source: HEDIS® 2021 (component of CDC)

Percentage of members 18–75 years of age with diabetes (type 1 and type 2) whose most recent Hemoglobin A1C is ≤9.0%.

Best Practice

• Review HbA1c Reporting that is made available on the User Interface. Highmark will issue an ad hoc HbA1c report which will indicate whether Highmark has received a claim indicating an HbA1c has been drawn – Y/N and if drawn if that test has been resulted to date. If a result has been received, the report will reflect the value received in the format it has been received (either CPT2 code or the actual lab value). All ad hoc reports are directional only and do not take into consideration continuous enrollment and other factors that determine a member’s inclusion into program resulting.

• This is an outcome control measure which requires disease management and the demonstration of controlled HbA1c lab values. HEDIS (CMS) requires the last result of the year to be the determinant of compliance and control.

• Highmark is required to submit all member claims data. Lab providers (outpatient labs and facilities) submit claims for payment, which influences the last test of the year. All “draw” claims without a resulting lab value are seen as non-compliant.

• Submit zero dollar (performance reporting only) CPT2 claims on every result received or result via CPT2 codes with next patient visit.

• Encourage partner facilities to include lab results with procedure claims submission.

Supplemental Data Submission

CQF function is available through the Provider Portal on NaviNet and accepts submission of numerator compliance and exclusionary data unavailable through claims or for Highmark members who had services prior to being a Highmark carrier.

Medicare Advantage Member Benefits

Covered in full. Office visit or site of service co-pay may apply.
Limits: 4 per calendar year
C16: Controlling High Blood Pressure

Source: HEDIS® 2021 (CBP)

Measure weight: 1
5 Star: 88%

Percentage of members 18-85 years of age who had a diagnosis of hypertension (HTN) and whose BP was adequately controlled during the measurement year (<140/<90 mm Hg).

<table>
<thead>
<tr>
<th>Numerator</th>
<th>Denominator</th>
<th>Exclusions</th>
</tr>
</thead>
</table>
| A representative systolic BP of <140 mm Hg and a representative diastolic BP of <90 mm Hg AND is the most recent BP reading during the measurement year (occurring on or after the second diagnosis of hypertension) during an outpatient office visit billed to Highmark. ** as defined by Hedis, TOC visits are not able to be used in reporting values for blood pressure measurement.**  
If no BP is recorded during the measurement year, assume that member is “not controlled”. | Members who had at least two visits on different dates of service with a diagnosis of hypertension during the first 6 months of the measurement year or the year prior to the measurement year (count services that occur over both years). 
Visit type need not be the same for the two visits. | Female members with a diagnosis of pregnancy  
Do not include BP readings on the following:  
• Taken during and acute inpatient stay or and ED visit.  
• Taken on the same day as a diagnostic test or diagnostic or therapeutic procedure that requires a change in diet or a change in medication on one day before the day of the test or procedure (with the exception of fasting blood tests)  
• Taken by the member using a non-digital device such as a manual blood pressure cuff and a stethoscope. |

Codes used to identify numerator compliance.

**Most recent Systolic:**
- 3074F: <130 mm Hg
- 3075F: 130-139 mm Hg

**Most recent Diastolic:**
- 3078F: <80 mm Hg
- 3079F: 80-89 mm Hg
C16: Controlling High Blood Pressure  
**Source:** HEDIS® 2021 (CBP)

Percentage of members 18-85 years of age who had a diagnosis of hypertension (HTN) and whose BP was adequately controlled (<140/90 mm HG) during the measurement year.

### Best Practice

- Identify patients 65 years and older who had at least two significant diagnoses of hypertension.
- This is an outcome control measure which requires disease management and the demonstration of controlled values. HEDIS (CMS) requires the last result of the year to be the determinant of compliance and control. 1500 clam submission of CPTII codes must match the date of service of an outpatient office visit claim.
- Develop and implement evidenced based guidelines to treat members identified with high blood pressure.
- Ensure that practice is submitting the appropriate CPTII code to Highmark for both systolic and diastolic values. Compliance for this measure requires both values to be within range.
- Provide ongoing outreach to non-compliant members.
- Implement care coordination to manage patients with values greater than 140mm Hg or values greater than 90 mm Hg diastolic.

### Supplemental Data Submission

CQF function is available through the Provider Portal on NaviNet and accepts submission of numerator compliance for services that are not submitted via claims such as nursing visits that are not billed to Highmark, or Specialist Visits where the PCP cannot submit matching claim data via NaviNet 1500 claims*.

*If the most recent blood pressure value occurred during a nursing visit only and a claim was not submitted to Highmark, or through a specialist visit not within the PCP practice, the CQF is available to submit the EMR visit note along with numerator compliant systolic and diastolic values.*
**DMC19: TRC Medication Reconciliation Post-Discharge**  
*Source: HEDIS® 2021 (TRC)*  

**Percentage of discharges in the measurement year for members 18 years of age and older for whom medications were reconciled on the date of discharge through 30 days after discharge.**

<table>
<thead>
<tr>
<th>Numerator</th>
<th>Denominator</th>
<th>Exclusions</th>
</tr>
</thead>
</table>
| Medication reconciliation conducted by a prescribing practitioner, clinical pharmacist or registered nurse on the date of discharge through 30 days after discharge (31 total days) in which the discharge medications are reconciled with the most recent medication list in the outpatient medical record. | Acute or nonacute inpatient discharges on or between JAN 1 and DEC 1 of the measurement year. | • If the discharge is followed by a readmission or direct transfer to an acute or nonacute inpatient care settings on the date of discharge through 30 days after discharge, count only the last discharge.  
• If the member remains in an acute or nonacute facility through December 1st of the measurement year.  
*Exclude both the initial and the readmission/direct transfer discharges if the last discharge occurs after DEC 1 of the measurement year.* |
| Measure is based on discharges, not members. If members have more than one discharge, include all discharges. | |

**Note:** Medication Reconciliation Post-Discharge measure is now a component of the Transitions of Care Measure.
DMC19: TRC Medication Reconciliation Post-Discharge

Source: HEDIS® 2021 (TRC)

Percentage of discharges in the measurement year for members 18 years of age and older for whom medications were reconciled the date of discharge through 30 days after discharge.

Best Practice

- Track Medication Reconciliation completion by downloading the MA Monthly Stars Gap Report.
- Coordinate with hospital partners for SNF discharges/transfers.

Note: If a member is admitted within 30 days of a discharge or transferred directly to a skilled nursing facility, the medication reconciliation is required after the SNF discharge.

Claims Submission

Discharge medications reconciled with the current medication list in outpatient medical record:
CPTII Code 1111F or Transition of Care CPT Codes 99495 or 99496
Medical Record Documentation Requirements

Any of the following meets criteria:

- Documentation of the current medications with a notation that the provider reconciled the current and discharge medications.

- Documentation of the current medications with a notation that references the discharge medications (e.g., no changes in medications since discharge, same medications at discharge, discontinue all discharge medications).

- Documentation of the member’s current medications with a notation that the discharge medications were reviewed.

- Documentation of a current medication list, a discharge medication list and notation that both lists were reviewed on the same date of service.

- Documentation of the current medications with evidence that the member was seen for post-discharge hospital follow-up with evidence of medication reconciliation or review. Requires documentation that indicates the provider was aware of the member’s hospitalization and discharge.

- Documentation in the discharge summary that the discharge medications were reconciled with the most recent medication list in the outpatient medical record. There must be evidence that the discharge summary was filed in the outpatient chart on the date of discharge through 30 days after discharge (31 total days).

- Notation that no medications were prescribed or ordered upon discharge.

Note: Only documentation in the outpatient chart meets the intent of the measure, but an outpatient visit is not required.
C21: All-Cause Readmission Rate

Source: HEDIS® 2021 (PRC)

The ratio of observed to expected acute inpatient stays and observation stays during the measurement year that were followed by an unplanned acute readmission or observation stay for any diagnosis within 30 days. Members may be readmitted to the same hospital or different one.

<table>
<thead>
<tr>
<th>Numerator</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medicare Advantage members with an unplanned acute inpatient readmission or observation stay for any diagnosis within 30 days of a previous inpatient or observation index discharge date</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Denominator</th>
</tr>
</thead>
<tbody>
<tr>
<td>Count of Index Hospital Stays or Observation Stays for Medicare Advantage members 18 years of age and older with an acute inpatient stay or observation stay with a discharge on or between the first day of the measurement year and 31 days prior to the last day of the measurement year.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Exclusions</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Hospital stays where the Index Admission Date is the same as the Index Discharge Date</td>
</tr>
<tr>
<td>- Inpatient stays and Observation stays with discharges for death</td>
</tr>
<tr>
<td>- Acute inpatient discharges or Observation stays with a principal diagnosis for pregnancy or for any other condition originating in the perinatal period</td>
</tr>
<tr>
<td>- *Outlier (Excluded from scoring) Members with 4 or more index hospital stays (including both inpatient and observation). Stays must occur between the first day of the measurement year and Dec 1st of the measurement year.</td>
</tr>
<tr>
<td>- Discharged inpatient or observation (index hospital) stays if the admission date of the first planned hospital stay is within 30 days and includes any of the following:</td>
</tr>
<tr>
<td>- Principal dx of maintenance chemotherapy or rehabilitation</td>
</tr>
<tr>
<td>- An organ transplant</td>
</tr>
<tr>
<td>- A potentially planned procedure w/out a principal acute diagnosis</td>
</tr>
</tbody>
</table>
All-Cause Readmission Rate
Source: HEDIS® 2021 (PCR)

Performance Metrics

• Stars Monthly Practice reports will again this year reflect both the actual readmission rate (readmissions/admissions) and then the trend compliance ratio value. The trend compliance calculation is the determinate of the Star rating.

The trend compliance data will be represented as a ratio:
Observed Readmissions/Expected Readmission.

*The expected readmission value is a complex risk adjusted model supplied by NCQA/HEDIS specifications. Incorporated risk adjustment categories are based on presence of surgeries, discharge condition, comorbidity, and age.*

Examples

A. Your practice has 100 acute inpatient discharges of which 20 were unplanned readmissions. Based on the application of the expected model to those 100 patients, 10 were expected to be readmitted. Your ratio is 20/10 or 2.00

B. Your practice has 100 acute inpatient discharges of which 20 were unplanned readmissions. Based on the application of the expected model to those 100 patients, 30 were expected to be readmitted. Your ratio is 20/30 or 0.66
C22: Statin Therapy for Patients with Cardiovascular Disease
Source: HEDIS® 2021 (SPC)

**Percentage of members who had at least one dispensing event for a high or moderate-intensity statin medication in the measurement year.**

<table>
<thead>
<tr>
<th>Numerator</th>
<th>Denominator</th>
<th>Exclusions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Members who filled at least one ambulatory prescription for high or moderate-intensity statin medication.</td>
<td>Male members ages 21–75 and females age 40–75 identified by event or diagnosis during the year prior to the measurement year who were: - Discharged from an inpatient setting with myocardial infarction - Had a CABG, PCI or other revascularization procedure in any setting OR - By Diagnosis, as having Ischemic Vascular Disease during both the measurement period and the year prior. Criteria need not be the same across both years but meet at least one of the following criteria:  - at least one acute inpatient encounter with an IVD diagnosis  - at least one outpatient encounter with an IVD diagnosis  - at least one telephone, e-visit, or Virtual check in with an IVD diagnosis</td>
<td>• Those with a diagnosis of cirrhosis in the measurement year or year prior.  • Those with a diagnosis of myalgia, myositis, myopathy or rhabdomyolysis during the measurement year.  • Those with a diagnosis of pregnancy during the measurement year or year prior.  • Those who have In vitro fertilization in the measurement year or year prior.  • Those who filled at least one prescription for clomiphene during the measurement year or year prior.  • Those without pharmacy benefits through Highmark.</td>
</tr>
</tbody>
</table>

*Note: Because this is a Part C Measure, prescriptions filled under commercial coverage will transition to numerator compliance for members that become newly enrolled in Medicare Advantage.*

Frailty and Advanced Illness exclusions apply
C22: Statin Therapy for Patients with Cardiovascular Disease
Source: HEDIS® 2021 (SPC)

Percentage of members who had at least one dispensing event for a high- or moderate-intensity statin medication in the measurement year.

<table>
<thead>
<tr>
<th>Description</th>
<th>Prescription (one Pharmacy claim required)</th>
</tr>
</thead>
</table>
| **High-Intensity Statin Therapy**  | • Atorvastatin 40-80 mg  
• Amlodipine-atorvastatin 40-80 mg  
• Rosuvastatin 20-40 mg  
• Simvastatin 80 mg  
• Ezetimibe-simvastatin 80 mg |
| **Moderate-Intensity Statin Therapy** | • Atorvastatin 10-20 mg  
• Amlodipine-atorvastatin 10-20 mg  
• Rosuvastatin 5-10 mg  
• Simvastatin 20-40 mg  
• Ezetimibe-simvastatin 20-40 mg  
• Pravastatin 40-80 mg  
• Lovastatin 40 mg  
• Fluvastatin XL 80 mg  
• Fluvastatin 40 mg bid  
• Pitavastatin 2-4 mg |

**Note:** NCQA will post a comprehensive list of medications and NDC codes to www.ncqa.org by NOV 1, 2021.
C22: Statin Therapy for Patients with Cardiovascular Disease

Source: HEDIS® 2021 (SPC)

Percentage of members who had at least one dispensing event for a high- or moderate-intensity statin medication in the measurement year

Best Practice

- Educate diabetic members on the increased risk of cardiovascular disease, so that they may understand the benefits of statin therapy in reducing their risk of stroke, heart attack and cardiovascular death

- Only select diagnoses can be submitted if statin therapy is contraindicated which would include myalgia, myositis, myopathy, and rhabdomyolysis (most popular listed below). Claim must be submitted within the measurement year with the appropriate diagnosis codes. Documentation in chart must be clear in stating. Phrasing of “intolerance”, "reaction”, and “cannot take” are not evidence enough for an exclusion.

- Review monthly gap reports and assure the member is on correct moderate or high dose medication to meet compliance

<table>
<thead>
<tr>
<th>Code</th>
<th>Diagnosis</th>
<th>ICD10CM</th>
</tr>
</thead>
<tbody>
<tr>
<td>G72.0</td>
<td>Drug-induced myopathy</td>
<td>ICD10CM</td>
</tr>
<tr>
<td>G72.2</td>
<td>Myopathy due to other toxic agents</td>
<td>ICD10CM</td>
</tr>
<tr>
<td>G72.9</td>
<td>Myopathy, unspecified</td>
<td>ICD10CM</td>
</tr>
<tr>
<td>M62.82</td>
<td>Rhabdomyolysis</td>
<td>ICD10CM</td>
</tr>
<tr>
<td>M79.1</td>
<td>Myalgia</td>
<td>ICD10CM</td>
</tr>
<tr>
<td>M60.9</td>
<td>Myositis, unspecified</td>
<td>ICD10CM</td>
</tr>
</tbody>
</table>
C22: Statin Therapy for Patients with Cardiovascular Disease
Source: HEDIS® 2021 (SPC)

Statin Intolerance and Statin-Induced Rhabdomyolysis

• Patient counseling:
  
  *Educate patient on the following:*
  
  - ASCVD risk score and rationale behind statin therapy
  - Risk factors associated with statin-induced rhabdomyolysis
  - Signs/symptoms of rhabdomyolysis

• Additional Considerations:
  
  - Studies show that almost half of patients can tolerate the same statin upon rechallenge.
  - Rosuvastatin, Pravastatin, and Fluvastatin are the least likely to have drug interactions.

• Alternative Dosing Options to Consider:
  
  - Lipitor (Atorvastatin): QOD (every other day)
  - Crestor (Rosuvastatin): QOD (every other day), twice weekly, OR once weekly

***If considering use of an alternate dosing schedule, please be sure the prescription is written and dispensed at the pharmacy with these directions. This will allow adherence to be measured properly – important for future measure if SUPD or SUPC moves to a denominator for statin adherence measure.
**D14: Statin Use in Persons with Diabetes**

*Source: PQA 2021 (SUPD)*

**Measure weight: 1**

**5 Star: 89%**

**Percentage of members who were dispensed a medication for diabetes that receive a statin medication.**

<table>
<thead>
<tr>
<th>Numerator</th>
<th>Denominator</th>
<th>Exclusions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Members who receive a prescription fill for a statin or statin combination during the measurement year.</td>
<td>Members aged 40–75* as of the first day of the measurement year who were dispensed two or more prescription fills on different dates of service for a hypoglycemic agent during the measurement year.</td>
<td>• Members with rhabdomyolysis or myopathy</td>
</tr>
<tr>
<td><em>Members that turn 76 within the measurement year require a Part D statin fill prior to turning 76 for Health Plan compliance.</em></td>
<td><em>The index prescription for the first hypoglycemic medication must occur at least 90 days prior to the end of the measurement year for denominator inclusion.</em></td>
<td>• Members with a diagnosis of pregnancy, lactation, or fertility.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Members with a diagnosis of liver disease</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Members with a diagnosis of pre-diabetes</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Members with a diagnosis of Polycystic Ovarian Syndrome (PCOS)</td>
</tr>
</tbody>
</table>
Percentage of members who were dispensed a medication for diabetes that receive a statin medication.

### PQA Table: Statin Medications

<table>
<thead>
<tr>
<th>Statin Medications</th>
</tr>
</thead>
<tbody>
<tr>
<td>lovastatin</td>
</tr>
<tr>
<td>rosuvastatin</td>
</tr>
<tr>
<td>fluvastatin</td>
</tr>
<tr>
<td>atorvastatin</td>
</tr>
<tr>
<td>pravastatin</td>
</tr>
<tr>
<td>pitavastatin</td>
</tr>
<tr>
<td>simvastatin</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Statin Combination Products</th>
</tr>
</thead>
<tbody>
<tr>
<td>niacin &amp; lovastatin</td>
</tr>
<tr>
<td>atorvastatin &amp; amlodipine</td>
</tr>
<tr>
<td>niacin &amp; simvastatin</td>
</tr>
<tr>
<td>ezetimibe &amp; simvastatin</td>
</tr>
</tbody>
</table>
Percentage of members who were dispensed a medication for diabetes that receive a statin medication.

**Best Practice**

- Educate diabetic members on the increased risk of cardiovascular disease, so that they may understand the benefits of statin therapy in reducing their risk of stroke, heart attack and cardiovascular death.

- Only select diagnoses can be submitted if statin therapy is contraindicated which would include myopathy and rhabdomyolysis. Claim must be submitted within the measurement year with the appropriate diagnosis codes. Phrasing of “intolerance”, “reaction”, and “cannot take” are not evidence enough for an exclusion.

- Review members chart for other exclusions that can be submitted to exclude member from the measure.

- Consider statins with fewer drug interactions such as rosuvastatin, pravastatin, and fluvastatin to reduce risk of adverse events.

- Members who do not tolerate one statin may be able to tolerate a different statin.

- Review monthly gap reports and assure the member is on correct medication to meet compliance.
D10: Medication Adherence for Diabetes Medications

Source: PQA 2021

Measure weight: 3  5 Star: 89%

**Percentage of members with a prescription for a diabetes medication who fill their prescriptions often enough to cover 80% or more of the time they are supposed to be taking the medication. The classes of diabetes medication includes: biguanides, sulfonylureas, thiazolidinediones, DDP_IV inhibitors, Incretin Mimetic Agents, Meglitinides, and SGLT2 Inhibitors.**

<table>
<thead>
<tr>
<th>Numerator</th>
<th>Denominator</th>
<th>Exclusions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Those members with a prescription for diabetes medication who fill their prescriptions often enough to cover 80% or more of the time they are supposed to be taking their medications. *</td>
<td>Members 18 years of age or older as of the first day of the measurement year with at least two fills on different dates of medication(s) across any of the drug classes during the measurement period.</td>
<td>• Those without pharmacy benefits through Highmark. • Members who take insulin</td>
</tr>
</tbody>
</table>

*Derived from the prescription daily dosage.*

**Note:** Medication Adherence for Diabetes medications have been updated, and NDC codes are progressive.
D11: Medication Adherence for Hypertension: Renin Angiotensin System Antagonists (RASA)

Source: PQA 2021

Percentage of members with a prescription for a blood pressure medication who fill their prescriptions often enough to cover 80% or more of the time they are supposed to be taking the medication. Blood pressure medication includes: ACE (angiotensin converting enzyme) inhibitor, ARB (angiotensin receptor blocker), a direct renin inhibitor or combinations thereof.

Measure weight: 3 5 Star: 90%

<table>
<thead>
<tr>
<th>Numerator</th>
<th>Denominator</th>
<th>Exclusions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Those members with a prescription for recommended hypertension medication who fill their prescriptions often enough to cover 80% or more of the time they are supposed to be taking their medications. *</td>
<td>Members 18 years of age or older as of the first day of the measurement year with at least two fills on different dates of medication(s) across either the same medication or medications (s) in the drug classes during the measurement period. Members are only included in the measure calculation if the first fill of their medication occurs at least 91 days before the end of the measurement period.</td>
<td>• Those without pharmacy benefits through Highmark. • Members who take sacubitril/valsartan.</td>
</tr>
</tbody>
</table>

*Derived from the prescription daily dosage.

Note: Medication Adherence for Hypertension medications have been updated, and NDC codes are progressive.
D12: Medication Adherence for Cholesterol: Statins

Source: PQA 2021

Percent of plan members with a prescription for a cholesterol medication (a HMG CoA Reductase Inhibitor-statin drug or statin combination) who fill their prescriptions often enough to cover 80% or more of the time they are supposed to be taking the medication.

<table>
<thead>
<tr>
<th>Numerator</th>
<th>Denominator</th>
<th>Exclusions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Those members with a prescription for a cholesterol medication (a statin drug or statin combination) who fill their prescriptions often enough to cover 80% or more of the time they are supposed to be taking their medications.*</td>
<td>Members 18 years of age or older as of the first day of the measurement year with at least two fills on different dates of either the same medication or medication(s) in the drug classes during the measurement period. Members are only included in the measure calculation if the first fill of their medication occurs at least 91 days before the end of the measurement period.</td>
<td>• Those without pharmacy benefits through Highmark.</td>
</tr>
</tbody>
</table>

*Derived from the prescription daily dosage.

Note: Medication Adherence for Cholesterol medications have been updated, and NDC codes are progressive.
D10, D11, D12: Medication Adherence Measures

Source: PQA 2021

Percentage of members who were dispensed a medication who fill their prescriptions often enough to cover 80% or more of the time they are supposed to be taking the medication.

**Best Practice**

- Identify all members who are prescribed medication for these categories
- Prep chart to ensure that provider discusses importance of ongoing compliance
- Discuss with the member the benefits of adhering to medication - Nurse/Physician/Medical assistant/Physician extender
- Utilize medication adherence report to identify those trending poorly on compliance
- Provide ongoing patient outreach to those showing as non-compliant
- Identify reason for noncompliance and attempt to solve
- Educate members about their condition and explain why the medication is being prescribed
- Use motivational interviewing to help members commit to taking their medication and set goals for taking their medications
- Ask members what routine they use to help them remember to take their medications (apps, alarms, pillboxes)
- Discourage "pill splitting" or taking medications every other day. If dosage changes, rewrite prescription to accurately show prescribed dose.
- Consider 90 day fills when writing prescriptions.
- Encourage members to utilize their insurance card, as this may help to identify other services that may be beneficial to them. Samples, paying in cash and using discount cards will not generate an insurance claim, and Highmark will not be able to measure compliance. These members will appear as non-compliant with the measure.
- Be proactive. Evaluate practice processes for opportunities to close gaps every time the member is seen rather than reacting to gap closure reports.
Highmark offers one of the most comprehensive drug formularies in the market. This includes several Preferred Generic Medications which are the lowest cost medications offered. During the Initial Coverage Phase, Preferred Generics can be as low as a $0 copay when filled at a Preferred Pharmacy for members with the Preferred Pharmacy benefit.

The chart below includes several commonly prescribed Preferred Generics that are covered on all Highmark Medicare Formularies.

<table>
<thead>
<tr>
<th>Preferred Generics</th>
<th>Cholesterol</th>
<th>Diabetes</th>
<th>Hypertension</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Atorvastatin</td>
<td>Glimepiride</td>
<td>Amlodipine-Benazepril</td>
</tr>
<tr>
<td></td>
<td>Lovastatin</td>
<td>Glipizide</td>
<td>Benazepril</td>
</tr>
<tr>
<td></td>
<td>Pravastatin</td>
<td>Glipizide Er</td>
<td>Benazepril-Hctz</td>
</tr>
<tr>
<td></td>
<td>Simvastatin</td>
<td>Glipizide-Metformin</td>
<td>Candesartan</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Metformin</td>
<td>Candesartan-Hctz</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Metformin Er (generic Glucophage Xr)</td>
<td>Captoril</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Nateglinide</td>
<td>Candesartan-Hctz</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Piozlitazone</td>
<td>Captoril</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Enalapril</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Enalapril-Hctz</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Fosinopril</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Fosinopril-Hctz</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Irbesartan</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Lisinopril</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Lisinopril-Hctz</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Losartan</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Losartan-Hctz</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Moexipril</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Perindopril</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Quinapril</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Quinapril-Hctz</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Ramipril</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Trandolapril</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Valsartan (excludes 320 mg)</td>
</tr>
</tbody>
</table>
**D13: Medication Therapy Management (MTM)**

Source: CMS 2021

Measure weight: 1 5 Star: 89%

**Percentage of MTM eligible members who received a Comprehensive Medication Review (CMR) during the measurement year. Source: Highmark developed measure.**

<table>
<thead>
<tr>
<th>Numerator</th>
<th>Denominator</th>
<th>Exclusions</th>
</tr>
</thead>
</table>
| Eligible members who complete a CMR by an approved CMS vendor during the measurement year.* | Members who meet eligibility requirements: | • Those that opt out within 60 days of program eligibility**
**Opt outs as determined by internal review will be reflected in member detail reports upon confirmation.** |

*While Highmark understands medication reconciliation is often completed by our network providers, this is a Medicare program that requires CMRs be conducted by a prior CMS approved party

<p>| | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Those with three or more chronic conditions, who take a minimum of seven Part D medications, and are likely to incur annual costs of at least $4,376 for all covered Part D drugs.</td>
<td>• Those enrolled less than 60 days of eligibility date and not active with Highmark (deceased or dis-enrolled per ECS) are excluded provided that no CMR is completed. If a CMR is completed during the member’s enrollment, then member is not excluded.</td>
</tr>
<tr>
<td></td>
<td>Targeted chronic conditions include: Bone Disease – Arthritis – Osteoporosis Bone Disease – Arthritis – Rheumatoid Arthritis Chronic Heart Failure Diabetes Dyslipidemia Mental Health – Depression Respiratory Disease – Chronic Obstructive Pulmonary Disease (COPD)</td>
<td></td>
</tr>
</tbody>
</table>

**Note:** Members in long-term care facilities are not excluded from the denominator.
D13: Medication Therapy Management (MTM)

Source: CMS 2021

Percentage of MTM eligible members who received a Comprehensive Medication Review (CMR) during the measurement year.

### Reporting Developed to Track Numerator/Denominator

Eligible members will be reflected on Monthly Stars Care Gap reports - CMR completion will be seen as compliant.

Eligible members may elect to opt out of CMR completion when contacted by the MTM Pharmacy Team; however, opt outs must be documented in the CMR system within 60 days of becoming MTM Program eligible to be removed from the denominator. Members who opt out after the 60 day time period will be denoted as non-compliant. Validation of opt outs is determined by internal review and will be reflected in member detail reports upon confirmation.

### Best Practice

Review Monthly Star Care Gap MTM detail reports for members that have become eligible.

Correct or add missing member information and notify Highmark Pharmacy Team to assist in contacting and scheduling CMRs for your attributed members.

Develop process for timely member contact and encourage completion of CMR with the MTM Pharmacy Team.

Discuss the benefits of completing the CMR with the members during AWV and other office visits.

To schedule a CMR on behalf of the member, use the MTM Referral Request Form located on the Provider Resource Center > Value-Based Reimbursement Programs > Medicare Advantage Stars > Medication Therapy Management> Practice Tools and fax to (833) 887-4676.
What is the MTM Program and how will it be conducted?

Program Specifics
- Medicare Part D covered benefit
- Designed to provide assistance to members with certain disease states who take many medications and have high prescription costs.
- Providers members access to a health care professional who can help support their health and safety and complement the care they receive by having a pharmacist work with them and their doctor.
- This program is free, and members are automatically enrolled if eligible.
- They will receive information on how to access the program and will be contacted to schedule/complete a CMR.

CMR/TMR
- During this one-on-one telephone consultation with a pharmacist or nurse, the member’s entire medication profile is reviewed (CMR – Comprehensive Medication Review), including prescriptions, over-the-counter (OTC) medications, herbal supplements, and samples. The pharmacist or nurse will check for appropriateness of therapy and potential interactions. They will also discuss therapy goals, medication-related problems and any specific questions the member may have. Targeted Medication Reviews (TMR) are also conducted focusing on identifying cost savings, safety concerns, prescribing adherence to national treatment guidelines and whether members have been following their medication regimens.
- CMR Follow-up Letter - This letter includes a Personal Medication List and Medication Action Plan detailing the member’s conversation with the pharmacist or nurse.
- Member / Doctor Outreach - If an issue is found during a medication review (CMR or TMR), the team may contact the member and/or doctor via phone, fax, or mail to discuss recommendations for adding or changing drug therapy, potential drug interactions or safety issues.
HOS1: Screening for Future Fall Risk

Source: NCQA (NQF: 0101)

Measure weight: 1
5 Star: 61%

Percentage of members aged 65 years and older who had a risk assessment for falls completed in the measurement year.

<table>
<thead>
<tr>
<th>Numerator</th>
<th>Denominator</th>
<th>Exclusions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Completed assessment of whether an individual has experienced a fall or problems with gait or balance. A specific screening tool is not required for this measure.</td>
<td>Members 65 years of age or older by the end of the measurement year who had a visit with an eligible provider* during the measurement year.</td>
<td>• Those with documentation of medical reason(s) for not screening for fall risk (i.e., patient is not ambulatory)</td>
</tr>
<tr>
<td>3288F - Falls risk assessment documented</td>
<td>*Any clinician with appropriate skills and the experience may preform the screening assessment.</td>
<td>1100F-1P, 1101F-1P – Patient not screened for future fall risk for medical reasons</td>
</tr>
<tr>
<td>1100F – Patient screened for future fall risk; documentation of two or more falls in the past year or any fall with injury in the past year</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1101F – Patient screened for future fall risk; documentation of no falls in the past year or only one fall without injury in the past year</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Use of 8P Modifier – Will not result patient as numerator compliant and will also cause other submissions to be voided for the measurement year.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
CMS uses the Medicare Health Outcomes Survey (HOS) to measure falls risk management for Medicare Advantage Members.

The survey asks about falls in the past 12 months, problems with balance or walking and whether their provider did anything to help prevent falls or treat problems with balance or walking.

Some things that may be suggested:
- Using a cane or walker
- Checking blood pressure lying or standing
- Exercising or physical therapy program
- Vision or hearing testing

The measure used in this Program (HOS1) serve as a proxy for the HOS measures. The rationale for development of these measures is to identify at-risk members to target for comprehensive risk-assessment and intervention, which is identified as the most important part of falls prevention. Family physicians have a pivotal role in screening older members for risk of falls, and applying preventive strategies for members at risk (al-Aama, 2011).

Best Practice Recommendations:
Complete during Annual Wellness Visits: Falls Risk Assessment; Improving Bladder Control; and Monitoring Physical Activity
## Best Practice

**Fracture Prevention/Assess Contributing Factors:**
- Remember that Fall Risk Assessments are part of the Annual Wellness Visit. If the requirements of the AWV are completed, then the requirements of for Fall Risk have been completed and a CPTII can be dropped with the AWV visit.
- Screen members at risk for osteoporosis (bone mineral density test)
- Assess Risk of Falls
- Screen for Urinary Incontinence
- Review and evaluate Use of High Risk Medications

## Important Fact about Falls

- One out of five falls causes a serious injury such as broken bones or a head injury.
- Each year, 2.8 million older people are treated in emergency departments for fall injuries.
- Over 800,000 patients a year are hospitalized because of a fall injury, most often because of a head injury or hip fracture.
- Each year at least 300,000 older people are hospitalized for hip fractures.
- More than 95% of hip fractures are caused by falling, usually by falling sideways.
- Falls are the most common cause of traumatic brain injuries (TBI).
- Adjusted for inflation, the direct medical costs for fall injuries are $31 billion annually. Hospital costs account for two-thirds of the total.

[https://www.cdc.gov/homeandrecreationalsafety/falls/adultfalls.html](https://www.cdc.gov/homeandrecreationalsafety/falls/adultfalls.html)
# C51: Annual Wellness/Initial Preventive Physical Physical Rate

**Source:** Highmark developed measure * 

**No weight assigned**

## Percentage of Medicare Advantage members who had the Annual Wellness Visit, or Initial Preventive Physical Exam within the measurement year.

<table>
<thead>
<tr>
<th>Numerator</th>
<th>Denominator</th>
<th>Exclusions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Members who completed the annual wellness visit after the first 12 months of enrollment in Medicare Part B. OR Members who completed the Initial Preventive Physical Examination (IPPE) during the first 12 months of enrollment in Medicare Part B.</td>
<td>Members 65 years of age or older by the end of the measurement year.</td>
<td>Member must be continuously enrolled during the measurement year.</td>
</tr>
<tr>
<td>Numerator Visit codes: G0402, G0438, G0439, G0468 (FQHC)</td>
<td></td>
<td>Member may not exceed more than a 45 day gap in enrollment.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Member must be enrolled in the plan at the end of the year.</td>
</tr>
</tbody>
</table>

Note: An Annual Physical Exam has been REMOVED from the Annual Wellness/IPPE measure specifications for numerator compliance.

*Not a CMS Star measure. C51 is eligible for gap closure incentive payments as well as determining performance level incentive multiplier.
Percentage of Medicare Advantage members who had the Annual Wellness Visit, or Initial Preventive Physical Exam within the measurement year.

### Reporting Developed to Track Numerator/Denominator

Highmark follows established CMS policy guidance on the billing/payment of AWV codes. The only exception is that Highmark allows the AWV to be billable once a calendar year.

CMS provides guidance on provider documentation requirements, and appropriate coding/billing. Reference sites have been attached below.


This means edits are in place to assure Highmark is:

- Paying for “Welcome to Medicare Visit” (G0402, Initial preventive physical exam) only when billed within the first 12 months of a member being enrolled in Medicare Part B.
- Not paying for multiple Annual Wellness Visits being billed within the same year.

As of 1-1-19 OSCAR benefits had coding put in place to pay for G0438 (AWV, initial) once per lifetime per provider practice and G0439 (AWV, subsequent) once per calendar year per provider practice.
Profiled/Informational Measures

The following clinical quality measures will be shown in reporting for informational purposes and in anticipation of future measure development.
### Percentage of members aged 65 years and older who had had a discussion regarding the presence or absence of urinary incontinence.

<table>
<thead>
<tr>
<th>Numerator</th>
<th>Denominator</th>
<th>Exclusions</th>
</tr>
</thead>
</table>
| Members who discussed with a provider within the measurement year the presence of absence of urinary incontinence. 1090F – Presence or absence of urinary incontinence assessed. 0509F – Urinary incontinence plan of care documented. | Medicare Advantage members 65 years of age or older. | • Member must be continuously enrolled during the measurement year.  
• Member may not exceed more than a 45 day gap in enrollment.  
• Member must be enrolled in the plan at the end of the year. |
HOS2: Improving Bladder Control
Source: Highmark (NCQA)

Percentage of members aged 65 years and older who had had a discussion regarding the presence or absence of urinary incontinence.

### HOS Survey

Given the fact that many people experience problems with urinary incontinence, or urine leakage, CMS uses the Medicare Health Outcomes Survey (HOS) to measure Bladder control for Medicare Advantage Members.

The survey asks if the member has talked with a doctor, nurse, or other health care provider about the leaking of urine? Specifically, during the past 6 months, how much did leaking of urine change daily activities or interfere with sleep?

Members may feel uncomfortable discussing incontinence with a doctor, but if incontinence is frequent or is affecting quality of life, it is important to seek medical advice. Urinary incontinence may:

- Indicate a more serious underlying condition
- Cause you to restrict your activities and limit your social interactions
- Increase the risk of falls in older adults as they rush to the toilet

The measure used in this Program (HOS2) serve as a proxy for the HOS measures. The rationale for development of these measures is to identify at-risk members to target for comprehensive risk-assessment and intervention.
HOS3: Monitoring Physical Activity

Source: Highmark (NCQA)

Percent of Medicare Advantage members who discussed exercise with their doctor and were advised to start, increase, or maintain their physical activity during the year.

<table>
<thead>
<tr>
<th>Numerator</th>
<th>Denominator</th>
<th>Exclusions</th>
</tr>
</thead>
</table>
| Medicare Advantage members that had a visit (in any setting) during the measurement period where exercise and physical activity was discussed with a certified medical professional. | Medicare Advantage members 65 years of age or older. | • Member must be continuously enrolled during the measurement year.  
• Member may not exceed more than a 45 day gap in enrollment.  
• Member must be enrolled in the plan at the end of the year. |

1003F – Level of activity assessed.  
Z71.82 – Exercise counseling
HOS3: Monitoring Physical Activity
Source: Highmark (NCQA)

Percent of Medicare Advantage members who discussed exercise with their doctor and were advised to start, increase, or maintain their physical activity during the year.

**HOS Survey**

To improve the overall health of our members, we are incorporating physical activity monitoring into our program to encourage members to engage in a regular exercise program approved by their doctor. This will be used in conjunction with the CMS Medicare Health Outcomes Survey (HOS) to measure physical activity for Medicare Advantage Members.

The survey asks if the member has with in the past 12 months, talked with a doctor or other health provider about a level of exercise or physical activity? For example, a doctor or other health provider may ask if the members exercises regularly or takes part in physical exercise.

Physical activity can help:
- Manage weight and improve physical strength
- Build and maintain healthy bones, muscles, and joints
- Improve balance and reduce your risk of falling
- Help elevate good cholesterol (HDL) while maintaining weight to help control bad cholesterol (LDL)
- Manage and prevent diseases like diabetes, heart disease, breast cancer, colon cancer, and osteoporosis
- Reduce feelings of depression, improve cognitive function, mood and overall well-being

The measure used in this Program (HOS3) serve as a proxy for the HOS measures. The rationale for development of these measures is to identify at-risk members to target for comprehensive risk-assessment and intervention.
# DMC18: Follow Up ED for People with Multiple Chronic Conditions

**Source:** HEDIS® 2021 (FMC)

The percentage of emergency department (ED) visits for members 18 years and older who have multiple high-risk chronic conditions who had a follow-up service within 7 days of the ED visit.

<table>
<thead>
<tr>
<th>Numerator</th>
<th>Denominator</th>
<th>Exclusions</th>
</tr>
</thead>
</table>
| A follow up service within 7 days after the ED visit (8 days total days). Include visits that occur on the date of the ED visit. Visits can meet criteria in any of the following settings:  
• Outpatient Visit  
• A telephone Visit  
• Transitional Care Management  
• Case Management Visits  
• Complex Care Management Services  
• An outpatient or telehealth behavioral health visit  
• An intensive outpatient encounter or partial hospitalization  
*Requires claim submission for numerator compliance* | An ED visit on or between Jan 1 and Dec 24th of the measurement year where the member was 18 years or older on the date of the visit and had at least two or more chronic conditions listed below within the measurement year or year prior to the measurement year:  
• COPD and Asthma  
• Alzheimer’s disease and related disorders  
• Chronic Kidney Disease  
• Depression  
• Heart Failure  
• Acute Myocardial Infarction  
• Atrial Fibrillation  
• Stroke and Transient Ischemic Attack | Exclude ED visits that result in an inpatient stay, regardless of the principal diagnosis for the admission.  
• Exclude ED visits followed by admission to an acute or nonacute inpatients care setting on the date of the ED visit or within 7 days after the ED visit, regardless of the principal diagnosis for the admission.  

Measure is based on ED visits, not members. If members have more than one ED visit, include all ED visits during appropriate time frame listed above.
The percentage of emergency department (ED) visits for members 18 years and older who have multiple high-risk chronic conditions who had a follow-up service within 7 days of the ED visit

**Best Practice**

- Monitor admission, discharge and ED visit reports
- Schedule post-discharge appointments within three to seven days.
- Educate members about their condition and provide extensive ongoing member outreach to manage chronic conditions
- Provide extensive ongoing member outreach to manage potential admissions and ED usage
**DMC21: Patient Engagement After Inpatient Discharge**

Source: HEDIS® 2021 (TRC)

<table>
<thead>
<tr>
<th><strong>Numerator</strong></th>
<th><strong>Denominator</strong></th>
<th><strong>Exclusions</strong></th>
</tr>
</thead>
</table>
| Documentation of patient engagement provided within 30 days after discharge. Do not include patient engagement that occurs on the date of discharge. Documentation must include,  
  - An outpatient visit (including home visits)  
  - A telephone visit  
  - A telehealth visit using audio and video  
  - An e-visit or virtual check-in  
  * Requires claim submission for numerator compliance | An acute or non acute inpatient discharge on or between January 1 and December 1 of the measurement year.  
  Measure is based on discharges, not members. If members have more than one discharge, include all discharges. |  
  - If the discharge is followed by a readmission or direct transfer to an acute or nonacute inpatient care settings on the date of discharge through 30 days after discharge, count only the last discharge.  
  - If the member remains in an acute or nonacute facility through December 1st of the measurement year.  
  * Exclude both the initial and the readmission/direct transfer discharges if the last discharge occurs after DEC 1 of the measurement year.|
The percentage of discharges for members 18 years of age and older who had documentation of patient engagement (e.g., office visits, visits to the home, telehealth) provided within 30 days after discharge

**DMC21: Patient Engagement After Inpatient Discharge**

Source: HEDIS® 2021 (TRC)

**Best Practice**

- Monitor admission, discharge and ED visit reports
- Schedule post-discharge appointments within three to seven days.
- Educate members about their condition and provide extensive ongoing member outreach to manage chronic conditions
- Provide extensive ongoing member outreach to manage potential admissions and ED usage
Thank you for your participation!